ATNM - Actinium hits over two-year high as Novartis executive joins to lead Iomab-B sales

• Actinium Pharmaceuticals ( NYSE: ATNM ), a biotech focused on targeted radiotherapies, announced Wednesday that former Novartis executive ( NVS ) ( OTCPK:NVSEF ) Caroline Yarbrough would join the company to lead its efforts to commercialize blood cancer therapy Iomab-B.
• The company said that Yarbrough, who most recently served the Swiss pharma giant as Portfolio General Manager for its U.S. Oncology operation, will take over as Actinium’s ( ATNM ) new Chief Commercial Officer.
• After ~81% gain over the past five days, the company share rose ~8% intraday to reach the highest level since August 2020 on the news.
• During her stint at Novartis ( NVS ), Yarbrough led the strategic account management of Kymriah, the first FDA-approved CAR-T cell therapy, Actinium ( ATNM ) added.
• Early this week, Actinium ( ATNM ) jumped ~26% after reporting positive data from a pivotal Phase 3 study involving patients with acute myeloid leukemia (AML).

For further details see: